Contact us
Company
Our approach
Pipeline Hacking aging Publications News & Events
GeroSense
Any question about our company, a partnership, or job opportunities?
Please complete our contact form and we will get in touch ASAP
Your name
Your e-mail
Company name
Message
By clicking submit below, you consent to allow Gero to store and process the personal information submitted above to provide you the content requested
CONTACT US

About Gero

Our mission: Hacking Complex Diseases and Aging with AI for Drug Discovery and Digital Biomarkers

GERO.AI utilizes Whole-Exome Sequencing data for in-human AI Drug Discovery, while GeroSense is the arm of Gero creating Digital Biomarkers. You can find more about GeroSense on the dedicated website.
GERO.AI models are originating from the physics of complex dynamic systems. We have presented our unique approach in Frontiers in Genetics. We combine the potential of deep neural networks with the physical models to study dynamical processes and undersend what drives a disease.
Gero conducts high-quality research studies backed by collaboration with researchers from the leading global institutions such as the Harvard Medical School, Massachusetts Institute of Technology, University of Edinburgh, National University of Singapore, and Roswell Park Comprehensive Cancer Center to develop new therapies. The company is a regular contributor to peer-reviewed journals, including recently accepted publication in Science.
Gero is funded by AI champions, including AIMATTER founders (recently acquired by Google). In 2019, Gero was also named one of the leading companies in artificial intelligence for lifespan extension along with Google and IBM.
Gero team
Сuring the uncurable with Landau Lifshitz book and a bit of AI
Peter Fedichev
CEO. Co-founder at Gero
I am doing my best to make aging a history.
Maxim Kholin
Co-founder at Gero
Deliver results of scientific work to the benefit of web and mobile users
Tim Pyrkov
Ph.D., mHealth R&D
Olga Burmistrova
Ph.D., Head of Preclinical Development
Science is a pricey thing. On a mission to fund science against aging.
Alex Kadet
Head of Business Development
"Omne possibile exigit existere."(Everything that is possible demands to exist.)
Alex Lyapin
Chief Financial Officer
Data Inquisitor
Konstantin Avchaciov
Data scientist - Life extension research
Ilya Sokolov
Data Scientist
Applying theoretical physics and AI to study the biology of aging.
Andrei Tarkhov
Ph.D., Principal Researcher
Right-hand-woman to aging hackers
Olga Druzhinina
Deputy Finance Director
Understanding the Universe, while providing real-world solutions
Kirill Denisov
Junior Deep Learning Researcher
Gero team
Сuring the uncurable with Landau Lifshitz book and a bit of AI
Peter Fedichev
CEO. Co-founder at Gero
I am doing my best to make aging a history.
Maxim Kholin
Co-founder at Gero
Deliver results of scientific work to the benefit of web and mobile users
Tim Pyrkov
Ph.D., mHealth R&D
Olga Burmistrova
Ph.D., Head of Preclinical Development
Science is a pricey thing. On a mission to fund science against aging
Alex Kadet
Head of Business Development
"Omne possibile exigit existere."(Everything that is possible demands to exist.)
Alex Lyapin
Chief Financial Officer
Data Inquisitor
Konstantin Avchaciov
Data scientist - Life extension research
Ilya Sokolov
Data Scientist
Applying theoretical physics and AI to study the biology of aging.
Andrei Tarkhov
Ph.D., Principal Researcher
Right-hand-woman to aging hackers
Olga Druzhinina
Deputy Finance Director
Understanding the Universe, while providing real-world solutions
Kirill Denisov
Junior Deep Learning Researcher
Key collaborators
Robert J. Shmookler Reis, PhD
Longevity pioneer, Professor and Udupa Chair in Geriatrics, Reynolds Institute on Aging/Dept. of Geriatrics; Professor of Biochemistry/Molecular Biology and Pharmacology/Toxicology, Univ. of Arkansas for Medical Sciences
Brian Kennedy, PhD
Distinguished Professor of Biochemistry and Physiology, Yong Loo Lin School of Medicine, NUS, Singapore, Buck Institute for Research on Ageing, Novato, CA, USA.
Andrei Gudkov, PhD
Senior Vice President of Research Programming and Development of Roswell Park Cancer Institute.CSO of Everon Biosciences, founded in 2010 in a partnership with Roswell Park Cancer Institute with the goal of developing anti-aging medicines.
Vadim Gladyshev, PhD
Professor of Medicine, professor at Harvard Medical School & Brigham and Women's Hospital. Expert and pioneer in antioxidant/redox biology
Yuri Aulchenko, PhD
CSO and Founder of PolyOmica
Honorary Professor of the University of Edinburgh, listed among "The World's Most Influential Scientific Minds" in the category "Molecular Biology & Genetics"by Thomson-Reuters.
Careers in GERO.AI
We are a next-gen AI for Drug Discovery company making cutting-edge science and continuously looking for great people to join a fast-growing team of like-minded pioneers to solve some of the most critical problems humanity faces.
We are looking for:
Machine Learning Research Scientist
We are looking for a research fellow who has an experience of working at an academic lab and has published their results in scientific papers.

Key responsibilities:
  • Analysis of time series of biological/physiological data 
  • Analysis of omics data
  • Development and testing physical models to describe and fit such data
  • Development of AI systems for insilico drug discovery and repositioning
  • Publication of results in scientific journals
Qualifications:
  • PhD in physics, computer science, biophysics or bioinformatics
  • Publications in scientific journals
  • Experience with basic python data-science packages: sklearn, numpy, pandas, scipy
  • Experience with artificial neural networks using Tensorflow or Pytorch
Software Engineer
Machine Learning Engineer
Business Development Associate (US)
Business Development Associate (EU)
Business Development Associate (APAC)
We are looking for:
Machine Learning Research Scientist
We are looking for a research fellow who has an experience of working at an academic lab and has published their results in scientific papers.

Key responsibilities:
  • Analysis of time series of biological/physiological data 
  • Analysis of omics data
  • Development and testing physical models to describe and fit such data
  • Development of AI systems for insilico drug discovery and repositioning
  • Publication of results in scientific journals
Qualifications:
  • PhD in physics, computer science, biophysics or bioinformatics
  • Publications in scientific journals
  • Experience with basic python data-science packages: sklearn, numpy, pandas, scipy
  • Experience with artificial neural networks using Tensorflow or Pytorch
Software Engineer
Machine Learning Engineer
Business Development Associate (US)
Business Development Associate (EU)
Business Development Associate (APAC)
Send CV